23 December 2024
Cambridge Cognition Holdings Plc
("Cambridge Cognition", the "Company" or the "Group")
Director/PDMR Share Purchases
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, was informed on 23 December 2024 that Nick Rodgers, Non-Executive Director of the Company, purchased 31,292 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 31.88 pence per share.
Following this transaction, Nick Rodgers holds an interest in 51,292 Ordinary Shares, representing approximately 0.12% of the Company's issued share capital.
Further information on the purchases is contained in the disclosure tables below.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||||
| a) | Name | Nick Rodgers | ||||||
| 2 | Reason for the notification | |||||||
| a) | Position/status | Non-Executive Director | ||||||
| b)
| Initial notification /Amendment | Initial notification | ||||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name | Cambridge Cognition Holdings Plc | ||||||
| b) | LEI | 213800SZKDIN122EPA96 | ||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of 0.01p each
GB00B8DV9647 | ||||||
| b) | Nature of the transaction | Purchase of Shares | ||||||
| c) | Price(s) and volume(s) |
| ||||||
| d) | Aggregated information - Aggregated volume - Price |
31,292 31.88 | ||||||
| e) | Date of the transaction | 23 December 2024 | ||||||
| f) | Place of the transaction | London Stock Exchange
| ||||||
Enquiries:
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a leading technology company specializing in digital health products that advance brain health research and treatment. The Company offers three core products: CANTAB® assessments, which provide scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform, with a large library of instruments, enabling efficient study set up and scalable data capture; and Quality Assurance Tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money. Together, these products improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.
For further information visit: https://cambridgecognition.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
